Table 1.
Demographic and clinical characteristics of patients in both groups.
| Patients' characteristics | Rivaroxaban | Warfarin | p value |
|---|---|---|---|
| (N = 147) | (N = 153) | ||
| Mean age ± SD | 68.25 ± 14.97 | 71.35 ± 13.09 | 0.0573 |
|
| |||
| Age ≥ 65 | 85 (57.82%) | 104 (67.97%) | 0.0738 |
| Age < 65 | 62 (42.18%) | 49 (32.03) | |
|
| |||
| Gender | |||
| Female | 77 (52.38%) | 83 (54.25%) | 0.8170 |
| Male | 70 (47.62%) | 70 (45.75%) | |
|
| |||
| Ethnic group | |||
| White | 113 (76.87%) | 133 (86.93%) | 0.0221† |
| AA | 14 (9.52%) | 4 (2.61%) | |
| Others | 20 (13.61) | 16 (10.46%) | |
|
| |||
| Indication for drug | |||
| AF | 69 (46.94%) | 93 (60.78%) | <0.0001† |
| VTE treatment | 12 (8.16%) | 56 (36.60%) | |
| VTE prophylaxis | 60 (40.82%) | 2 (1.31%) | |
| Other | 6 (4.08%) | 2 (1.31%) | |
|
| |||
| Low dose | 60 (40.82%) | NA | |
|
| |||
| High dose | 87 (59.18%) | NA | |
|
| |||
| Mean duration being on drug (Days) ± SD | 92.19 ± 119.91 | 252.95 ± 167.91 | <0.0001† |
|
| |||
| Duration ≤40 days | 81 (55.10%) | 16 (10.46%) | <0.0001† |
|
| |||
| Concomitant with aspirin | 56 (38.10%) | 63 (41.18%) | 0.6372 |
|
| |||
| Concomitant with thienopyridine | 12 (8.16%) | 27 (17.65%) | 0.0163 |
|
| |||
| Dual antiplatelet agents | 8 (5.44%) | 15 (9.80%) | 0.1558 |
|
| |||
| Concomitant with NSAIDs | 14 (9.52%) | 7 (4.58%) | 0.1144 |
|
| |||
| Hb < 12 | 55 (39.29%) | 54 (35.29%) | 0.5454 |
| Missing data | 7 | 0 | |
|
| |||
| Cr > 1.5 | 6 (4.23%) | 15 (9.80%) | 0.0714 |
| Missing data | 5 | 0 | |
|
| |||
| GFR ≤ 30 | 2 (1.41%) | 6 (3.92%) | 0.2851 |
| Missing data | 5 | 0 | |
|
| |||
| ALT > 40 | 11 (9.91%) | 28 (20%) | 0.0349† |
| Missing data | 36 | 13 | |
|
| |||
| BMI | |||
| <18.5 | 5 (3.52%) | 0 (0%) | 0.0707 |
| 18.5–24.9 | 31 (21.83%) | 35 (22.88%) | |
| >25 | 106 (74.65%) | 118 (77.12%) | |
| Missing data | 5 | 0 | |
|
| |||
| Previous GI bleeding | 5 (3.40%) | 15 (9.80%) | 0.0356† |
AA: African American, AF: atrial fibrillation, ALT: alanine aminotransferase, BMI: body mass index, Cr: creatinine, GFR: glomerular filtration rate, GI: gastrointestinal, Hb: hemoglobin, NSIADs: nonsteroidal anti-inflammatory drugs, and VTE: venous thromboembolism events. †Signifying statistical significant values.